|
|
3280 Bayshore Boulevard
Brisbane, CA 94005 USA
phone:(415) 466-2200
fax:(415) 466-2300
|
|
| Symbol |
ITMN |
| Exchange |
NASDAQ |
| Founded |
0 |
| Employees |
260 |
|
|
| www.intermune.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| InterMune, Inc. is a biopharmaceutical company focused on pulmonary, infectious and hepatic diseases. |
|
| Management |
| Daniel G. Welch, Chairman, Chief Executive Officer and President; Marianne Armstrong, Ph.D., Chief Medical Affairs and Regulatory Officer; Williamson Bradford, M.D., Ph.D., Senior Vice President, Clinical Science and Biometrics; John Hodgman, Senior Vice President and Chief Financial Officer; Steven Porter, M.D., Ph.D., Chief Medical Officer |
| |
|
|
|
|
|
|
|
| Keywords |
| granulomatous, osteopetrosis, cgd, actimmune, congenital |
|
|
|
| Description |
|
InterMune, Inc. is an independent biopharmaceutical company focused on developing and commercializing products for the treatment of serious pulmonary, infectious and hepatic diseases. The Company has three marketed products, growing product revenues and advanced-stage clinical programs addressing a range of diseases with attractive markets. Its three marketed products are Actimmune, Infergen and Amphotec. Actimmune is approved in the United States for two rare congenital disorders: chronic granulomatous disease and severe malignant osteopetrosis. InterMune markets Infergen in the United States and Canada for the treatment of chronic hepatitis C infections. It markets Amphotec worldwide for the treatment of invasive aspergillosis. |
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
